CervoMed Inc.

CervoMed announced that its investigational drug neflamapimod has been granted an Innovation Passport under the UK's Innovative Licensing and Access Pathway for the treatment of dementia with Lewy bodies. The designation, awarded by joint consensus of the Medicines and Healthcare products Regulatory Agency, the National Health Service, and health technology assessment bodies, recognizes neflamapimod as an innovative therapy addressing a condition of high unmet need with the potential to offer a major therapeutic advantage. The program provides early and coordinated guidance to help accelerate time to market and patient access. Neflamapimod is an oral small molecule that inhibits p38 MAP kinase, and in a Phase 2b trial it improved cognitive and functional outcomes in patients with DLB. CervoMed is currently seeking a strategic partner to advance neflamapimod into a Phase 3 trial.

CervoMed announced new clinical, plasma biomarker, and imaging data for neflamapimod in dementia with Lewy bodies at the Alzheimer's Association International Conference 2026. New analyses from the 159-patient Phase 2b RewinD-LB trial indicate that the failure to replicate earlier Phase 2a results was due to a higher-than-targeted proportion of patients with Alzheimer's disease co-pathology and use of a drug batch that did not achieve expected plasma concentrations. Exploratory analyses showed neflamapimod slowed worsening of DLB in patients with low plasma pTau181 and in those who achieved expected drug levels, with a consistently improving treatment effect at progressively lower pTau181 levels. Neflamapimod also demonstrated durable slowing of right basal forebrain atrophy and increased basal forebrain connectivity relative to placebo over 48 weeks. A separate Phase 2 study of an 80 mg twice-daily dose met its primary safety, tolerability, and pharmacokinetic objectives, and a pharmacokinetic-pharmacodynamic analysis identified a plasma trough threshold of about 4 ng/mL associated with clinical improvements, supporting selection of a 50 mg three-times-daily dose for the planned Phase 3 trial.

CervoMed has completed enrollment in its Phase 2a study of neflamapimod for nonfluent variant primary progressive aphasia, a type of frontotemporal dementia. The trial enrolled 25 participants who will receive oral neflamapimod for 24 weeks, followed by a 12-week randomized, double-blind placebo-controlled extension. Interim biomarker data from the study will be presented at the 19th Clinical Trials on Alzheimer's Disease conference in Boston in November 2026, with first clinical data expected in the first quarter of 2027. The company also highlighted a recent Nature Neuroscience publication demonstrating that p38α inhibition with neflamapimod reversed axonal transport deficits in a mouse model of tau-related frontotemporal dementia. Nonfluent variant primary progressive aphasia, the most common tau-associated frontotemporal dementia subtype, has no approved treatments in the United States or European Union.

CervoMed announced it will feature five presentations at the Alzheimer's Association International Conference 2026 in London from July 12 to 15, including four on its oral drug candidate neflamapimod for dementia with Lewy bodies. The presentations will cover exploratory Phase 2 analyses showing neflamapimod slowed clinical worsening in patients with low plasma p-tau181 and higher drug concentrations, its impact on basal forebrain atrophy as measured by MRI from the RewinD-LB trial, the plasma drug exposure-response relationship focusing on pharmacokinetic-pharmacodynamic relationships, and the first clinical data for an 80 mg twice-daily dose from a 24-week open-label study assessing safety, tolerability, and pharmacokinetics. A fifth presentation will address the development of a Goal Area Inventory for dementia with Lewy bodies using Goal Attainment Scaling to assess treatment response. Neflamapimod is an investigational oral small molecule that inhibits p38 MAP kinase, and the company is seeking a strategic partner to advance it into a Phase 3 trial for dementia with Lewy bodies.

CervoMed shares soared more than 80% on Tuesday with key clinical trial catalysts ahead, leading a group of biotech gainers. The company's lead drug candidate Neflamapimod is in development for dementia with Lewy bodies, with a Phase 3 trial planned for the second half of 2026, and has been selected for the EXPERTS-ALS platform in the UK, with first patient dosing anticipated in the fourth quarter of 2026. Simulations Plus agreed to be acquired by affiliates of Altaris for $375 million, or $18.50 per share, a 26% premium to its 60-day volume-weighted average price. NeOnc Technologies received its first international regulatory clearance from the Department of Health - Abu Dhabi to begin a Phase 2 trial of NEO212 for aggressive brain tumors. Lunai Bioworks regained compliance with Nasdaq's minimum bid price requirement, securing its listing. Other notable movers included Conexeu Sciences, which expanded its board and appointed a chief commercial officer, and Certara, which integrated its D360 platform with Secondary Intelligence software to improve off-target safety risk evaluation.